COVID-19 Treatments: Research Shows Treatment With Interferon-α2b Accelerates Recovery of COVID-19 Patients
Source: COVID-19 Treatments May 15, 2020 4 years, 5 months, 4 weeks, 2 days, 10 hours, 9 minutes ago
COVID-19 Treatments: A collaborative research between Canadian, Chinese and Australian researchers has demonstrated that treatment with interferon IFN-α2b was shown for the first time to be able improve virus clearance and decrease levels of inflammatory markers in a cohort study of COVID-19
patients.
.jpg)
The research findings were published in the journal
Frontiers in Immunology.
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full
The researchers co-led by Dr Qiong Zhou from Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan said that COVID-19 treatment with antivirals such as interferons may significantly improve virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
Interferons (IFNs) are a group of soluble glycoproteins that are produced and released from cells in response to virus infection (and other stimuli).
The team conducting an exploratory study on a cohort of confirmed COVID-19 cases in Wuhan found that treatment with interferon (IFN)-α2b significantly reduced the duration of detectable virus in the upper respiratory tract and reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in the human body. The findings show potential for the development of an effective antiviral intervention for COVID-19, which is an ongoing global pandemic caused by the novel coronavirus, SARS-CoV-2.
Dr Eleanor Fish of the Toronto General Hospital Research Institute & University of Toronto’s Department of Immunology and lead author told Thailand Medical News, “Interferons are our first line of defense against any and all viruses but viruses such as corona-viruses have co-evolved to very specifically block an interferon response. This informs us of the importance of interferons for the clearance of virus infections. Treatment with interferon will override the inhibitory effects of the virus.”
Dr Fish says that the study team considered IFN-α therapy for COVID-19 after they demonstrated interferons had therapeutic benefits during the SARS outbreak of 2002 and 2003.
AN URGENT APPEAL: Please help support this website by kindly making a donation to sustain this website and also all in all our initiatives to propel further research: https://www.thailandmedical.news/p/sponsorship
He further added, “The research sub-teams conducted a clinical study in Toronto to evaluate the therapeutic potential of IFN-α against SARS. Our findings were that interferon treatment sped up the resolution of lung abnormalities in patients treated with interferon compared with those not treated with interferon.”
Fo
r the research, , the team examined the course of disease in a cohort of 77 individuals with con-firmed COVID-19 admitted to Union Hospital, Tongii Medical College, Wuhan. The individuals evaluated in this study consisted of only moderate cases of COVID-19, as none of the patients required intensive care or oxygen supplementation or intubation.
The patients were either treated with IFN-α2b, arbidol (ARB), which is a broad-spectrum antiviral, or a combination of IFN-α2b plus arbidol, and viral clearance was defined as two consecutive negative tests for virus at least 24 hours apart, from throat swab samples.
The medical researchers demonstrated a significantly different rate of viral clearance for each treatment group and notably, IFN-α2b treatment accelerated viral clearance by approximately 7 days.
It was observed that treatment with IFN-α2b, whether alone or in combination with arbidol, accelerated viral clearance when compared to arbidol treatment alone. IFN treatment was also demonstrated to significantly reduce circulating levels of IL-6 and CRP, whether alone or in combination with arbidol.
Furthermore, the influence of age, co-morbidities and sex did not negate the effects of IFN treatment on viral clearance times or on the reduction in the inflammatory proteins IL-6 and CRP.
Even with the study’s limitations of a small, non-randomized cohort, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-α2b accelerated viral clearance from the upper respiratory tract and also reduced circulating inflammatory biomarkers, hinting at functional connections between viral infection and host end organ damage by limiting the subsequent inflammatory response in the lungs of patients.
Dr Fish further elaborates, “Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment. Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Dr Fish says a randomized clinical trial is a crucial next step, “A clinical trial with a larger cohort of infected patients that are randomized to treatment with interferon-alpha or to a placebo would further this research”.
The research findings from this study are the first to suggest therapeutic efficacy of IFN-α2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
For more on the latest
COVID-19 Treatments, keep checking at Thailand Medical news.
AN URGENT APPEAL: Please help support this website by kindly making a donation to sustain this website and also all in all our initiatives to propel further research: https://www.thailandmedical.news/p/sponsorship
